A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Plasma levels for SB-715992 and Capecitabine
will be checked at Day 1 for Cycle 1.
GSK Clinical Trials, MD
United States: Food and Drug Administration
|GSK Investigational Site||Fort Worth, Texas 76104|